Clinical Trials Logo

Salivary Gland Cancer clinical trials

View clinical trials related to Salivary Gland Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05390294 Completed - Clinical trials for Salivary Gland Cancer

Survival With Patients Treated With Salivary Gland Cancer

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival

NCT ID: NCT04291300 Completed - Clinical trials for Adenoid Cystic Carcinoma

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

LUPSA
Start date: May 26, 2020
Phase: Phase 2
Study type: Interventional

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

NCT ID: NCT03602079 Completed - Prostate Cancer Clinical Trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Start date: July 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

NCT ID: NCT03319641 Completed - Clinical trials for Adenoid Cystic Carcinoma

PSMA-PET Imaging for Advanced ACC/SDC

Start date: October 25, 2017
Phase: N/A
Study type: Interventional

Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy

NCT ID: NCT01703455 Completed - Clinical trials for Salivary Gland Cancer

Activity of Sorafenib in Salivary Gland Cancer

Start date: September 2010
Phase: Phase 2
Study type: Interventional

This is a single agent, prospective, open-label, monocenter, phase II trial of sorafenib in patients with recurrent and/or metastatic salivary gland carcinoma. This trial will be conducted with the primary aim to determine the response rate (CR+PR) according to the RECIST criteria. Response rate according to CHOI criteria, correlation between CHOI criteria and outcome, disease Control Rate (DCR) and acute toxicity will be evaluated as secondary objectives.

NCT ID: NCT01344356 Completed - Clinical trials for Nasopharyngeal Carcinoma

Stereotactic Body Radiotherapy for Head and Neck Tumors

Start date: July 2008
Phase: Phase 4
Study type: Interventional

This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.

NCT ID: NCT00886132 Completed - Clinical trials for Adenoid Cystic Carcinoma

A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This is a phase II study to evaluate the effectiveness of study drug sunitinib malate in patients with recurrent and/or metastatic adenoid cystic carcinomas of the salivary gland. There currently is not standard of care for this type of cancer and it has hoped that sunitinib will have antitumor effects on patients with this type of cancer.

NCT ID: NCT00509002 Completed - Clinical trials for Salivary Gland Cancer

Iressa Study in Patients With Salivary Gland Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.